Bio Weekly: Launchpad in Review, AI-Driven Stem Cell Research, UpBit Listing, IP Pipeline Update

Highlights from the last week in the Biosphere 🌐

Launchpad in Review

Bio's chief product officer @cl2pp discussed lessons learned from the first season of launches on Bio V2 and changes coming to the launchpad.

Over 8,000 users joined the first wave of projects on the Bio V2 Launchpad tokenizing AI co-scientists and biotech IP across stem-cell research, men's health, psychedelic science & more.

"With these first launches complete, we now have a wealth of data on launchpad performance and incentive mechanisms design," Clemens wrote, highlighting key learnings that are shaping the upcoming next season of Bio, including:

• Improving BIO staking incentives by putting it at the center of XP rewards and publishing transparent staking formulas.
• Sunsetting Yapping XP in its previous format in favor of a more sustainable way to reward creators.
• Improving launch mechanics and post-TGE trading, routing & liquidity operations to guarantee a seamless user experience and better aligned incentives among participants and project teams.

Read Clepp's full post, and stay tuned for more details on the upcoming Season 2 of the Bio Launchpad:

IP Pipeline Update

We covered scientific progress in the Bio Ecosystem spotlighting updates across live research projects and scientific IP in the network. Pipeline reviews covered projects in the fields of longevity, brain health, psychadelic science, fertility, rare diseases & more, including:

➤ @Cerebrum_DAO neuroscience programs: Percepta clinical study, FissionBio Mitochondrial ROS inhibitors have been validated, Transfidelity accepted in Neural Regeneration Research, Upcoming: @NEURONGale project exploring Galectin-3 inhibition to treat Alzheimer’s.